WHO Model Formulary, 2004


Book Description




The Selection and Use of Essential Medicines


Book Description

This report presents the recommendations of the WHO Expert Committee responsible for updating the WHO Model List of Essential Medicines. The first part contains a progress report on the new procedures for updating the Model List and the development of the WHO Essential Medicines Library. It continues with a section on changes made in revising the Model List followed by a review of some sections such as hypertensive medicines and fast track procedures for deleting items. Annexes include the 13th version of the Model List and items on the list sorted according to their 5-level Anatomical Therapeutic Chemical classification codes.




The Selection and Use of Essential Medicines


Book Description

This report presents the recommendations of the WHO Expert Committee responsible for updating the WHO Model List of Essential Medicines. The first part provides a brief description of the Open Session of the Committee followed by updates on the Model Formulary and the Essential Medicines Library the Priority Medicines Project and current activities in the field of rational use. There are also progress reports on the review of essential medicines for reproductive health and of the New Emergency Health Kit. The second part presents summaries of the Committee's considerations and justifications for the various deletions additions and changes to the Model List. Annexes to the main report include the 14th WHO Model List of Essential Medicines and a list of all items on the Model List sorted according to their 5-level Anatomical Therapeutic Chemical (ATC) classification codes.




Neonatal Formulary


Book Description

The Neonatal Formulary is a unique book providingadvice on the safe use of drugs during pregnancy, labour andthroughout the first year of life. Thoroughly updated, this fifthedition draws on the experience of an increasingly internationalgroup of neonatologists and is now a well established reference onprescribing in infancy. It covers all the drugs commonly used inthe perinatal period, including those used for fetal treatment, andsummarizes how the prescribing of each has to adapt to changes indrug elimination during the first year of life. Key features for the fifth edition include: fully updated monographs and references 20 full monographs for diseases more commonly seen in thetropics invaluable information on dose sizes and administration forbabies further inclusion of evidence from relevant RCTs and systematicreviews from the Cochrane database a free access website with regular updates and links to otheruseful information. ahref="http://www.blackwellpublishing.com/medicine/bmj/nnf5/updates.asp"IMPORTANTDOSAGE CHANGE/a




Neonatal Formulary


Book Description

Now in its sixth edition, the Neonatal Formulary continues to provide advice on the safe use of drugs commonly given to babies during labor, delivery and the first month of life. In addition to the 230 monographs featured in the previous edition, 6 new drugs were added and all references have been updated. An accompanying website offers regular updates and electronic cross-links to a wide range of other useful information for neonatologists and neonatal nurses, hospital pharmacists, obstetric staff or general practitioners. For easy access, the whole text is also available for purchase in a PDA format.




Making Medicines Affordable


Book Description

Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.




Antimicrobial Chemotherapy


Book Description

Instilling good prescribing habits in young doctors is essential for the benefit of patients and to preserve the value of the antibiotic revolution that altered medical practice in the second half of the twentieth century. These concerns underlie the approach taken in the new edition of this successful book. The text provides a comprehensive and up-to-date account of the principles of antimicrobial chemotherapy as an aid to informed, rational prescribing. Care is taken to address all aspects of antimicrobial drug use, including those specific to developed and developing countries of the world. The authors are international experts with a long standing interest in the role of education as a means of promoting an understanding of the benefits and limitations of antimicrobial chemotherapy in physicians, surgeons and other health care workers. The book offers a structured approach to the subject in four themed sections, each of several chapters. A historical introduction is followed by a section outlining the basic properties of antibacterial, antifungal, antiparasitic and antiviral (including antiretroviral) drugs.The next section explains the various facets of antimicrobial drug resistance - which threatens to undermine the continued efficacy of antimicrobial agents - and effective ways of countering the threat. Therapeutic use is covered in two sections: one introduces readers to the general principles that inform the rational prescribing of antimicrobial drugs; the second deals with practicalities of the use of antimicrobial agents in specific clinical conditions. The book ends with a description of the ways in which drugs are developed and marketed. There are extensive recommendations for further reading.




Best Practices: Position and Guidance Documents of ASHP


Book Description

The Most Comprehensive Set of Quality Guidelines Available to the Pharmacy Profession ASHP positions and more than 80 ASHP guidance documents of varying scope provide ongoing advice to practitioners and health systems to help improve the medication-use process, patient care and safety, and patient outcomes and quality of life. ASHP Statements ASHP Guidelines Technical Assistance Bulletins Therapeutic Position Statements Therapeutic Guidelines ASHP-Endorsed Documents




WHO guideline on country pharmaceutical pricing policies


Book Description

In recent years, high prices of pharmaceutical products have posed challenges in high- and low-income countries alike. In many instances, high prices of pharmaceutical products have led to significant financial hardship for individuals and negatively impacted on healthcare systems' ability to provide population-wide access to essential medicines. Pharmaceutical pricing policies need to be carefully planned, carried out, and regularly checked and revised according to changing conditions. Strong, well-thought-out policies can guide well-informed and balanced decisions to achieve affordable access to essential health products. This guideline replaces the 2015 WHO guideline on country pharmaceutical pricing policies, revised to reflect the growing body of literature since the last evidence review in 2010. This update also recognizes country experiences in managing the prices of pharmaceutical products.




WHO Expert Committee on Specifications for Pharmaceutical Preparations


Book Description

This report presents the recommendations of an international group of experts convened by the World Health Organization to consider matters concerning the quality assurance of pharmaceuticals and specifications for drug substances and dosage forms. Important topics were addressed such as regulatory guidance on interchangeability of medicines fix-dose combinations: how to regulate them new guidance in the area of good manufacturing practices (GMP) and stability testing and counterfeit medicines. In addition some 12 new monographs for antiretrovirals 6 new ones on TB drugs including 2- 3- and 4-fixed-dose preparations as well as monographs for antimalarial medicines are discussed in detail. Seven new specifications for antiretrovirals were adopted. The report also includes newly International Chemical Reference Substances for the series of artemisinin derivatives. The following new WHO guidelines were adopted and are annexed to the report: GMP: requirement for the sampling of starting materials (amendment to current text) GMP: water for pharmaceutical use guideline for sampling of pharmaceuticals and related materials guidelines for registration of fixed-dose combination medicinal products.